The expression of CD36 in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model

Neuropathology and Applied Neurobiology

Volumn 37, Issue 7, 2011, Pages 727-737

  Ueno, M ^a   Nakagawa, T ^a   Nagai, Y ^a   Nishi, N ^a   Kusaka, T ^a   Kanenishi, K ^a   Onodera, M ^a   Hosomi, N ^c   Huang, C ^d   Yokomise, H ^b   Tomimoto, H ^e   Sakamoto, H ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e MIE UNIVERSITY   (Japan)

Author keywords

Blood brain barrier; CD36; Hypertension; SHRSP

Indexed keywords

CD36 ANTIGEN; COLLAGEN; FREE RADICAL; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; SCAVENGER RECEPTOR B;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD VESSEL; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; WESTERN BLOTTING; WISTAR KYOTO RAT;

ANIMALS; ANTIGENS, CD36; BLOOD-BRAIN BARRIER; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HIPPOCAMPUS; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; STROKE;

EID: 80055079744     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2011.01172.x     Document Type: Article

References (53)

1. Sabbatini M, Strocchi P, Vitaioli L, Amenta F. The hippocampus in spontaneously hypertensive rats: a quantitative microanatomical study. Neuroscience 2000; 100: 251-8.
2. Sabbatini M, Catalani A, Consoli C, Marletta N, Tomassoni D, Avola R. The hippocampus in spontaneously hypertensive rats: an animal model of vascular dementia. Mech Ageing Dev 2002; 123: 547-59.
3. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27: 282-93.
4. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke prone spontaneously hypertensive rat. Circ Res 1974; 34/35: 143-53.
5. Yamori Y, Nagaoka A, Okamoto K. Importance of genetic factors in hypertensive cerebrovascular lesions. Jpn Circ J 1974; 38: 1095-100.
6. Hazama F, Ooshima A, Tanaka T, Tomimoto K, Okamoto K. Vascular lesions in the various substrains of spontaneously hypertensive rats and the effects of chronic salt ingestion. Jpn Circ J 1975; 39: 7-22.
7. Wardlaw JM, Sandercock PAG, Dennia MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34: 806-12.
8. Ueno M, Sakamoto H, Tomimoto H, Akiguchi I, Onodera M, Huang CL, Kanenishi K. Blood-brain barrier is impaired in the hippocampus of young adult spontaneously hypertensive rats. Acta Neuropathol 2004; 107: 532-8.
9. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure, and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic. Role of nitric oxide. Hypertension 1998; 32: 59-64.
10. Vaziri ND, Ni Z, Oveisi F, Trnavsky-Hobbs DL. Effect of antioxidant therapy on blood pressure, and NO synthase expression in hypertensive rats. Hypertension 2000; 36: 957-64.
11. Adler S, Huang H. Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol Renal Physiol 2004; 287: F907-F913.
12. Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, Kalaria RN, Kihara T, Asada-Utsugi M, Kinoshita A, Takahashi R. Chronic cerebral hypoperfusion accelerates amyloid β deposition in APPSwInd transgenic mice. Brain Res 2009; 1294: 202-10.
13. Parks JK, Smith TS, Trimmer PA Jr, Bennett JP Jr, Parker WD. Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 2001; 76: 1050-6.
14. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Rev Neurosci 2004; 5: S18-S25.
15. Deane R, Wu Z, Zlokovic BV. RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier. Stroke 2004; 35: 2628-31.
16. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004; 89: 807-11.
17. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
18. Fryer JD, DeMattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Hlotman DM. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem 2005; 280: 25754-9.
19. Abdulkarim Y, Hameed Z. Is the LDL receptor involved in cortical amyloid protein clearance? Neurochem Res 2006; 31: 839-47.
20. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV. Clearance of amyloid-β by circulating lipoprotein receptors. Nat Med 2007; 13: 1029-31.
21. Cao D, Fukuchi K, Wan H, Kim H, Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging 2006; 27: 1632-43.
22. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance. Neuron 2009; 64: 632-44.
23. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB. Beta-amyloid efflux mediated by p-glycoprotein. J Neurochem 2001; 76: 1121-8.
24. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El-Khoury JB. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 2002; 160: 101-12.
25. Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, Shen W, Dunlop NM, Gao JL, Murphy OM, Oppenheim JJ, Wang JM. Amyloid(beta)42 activates a G-protein-coupled chemoattractant receptor, FRP-like-1. J Neurosci 2001; 21: RC123-127.
26. Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, Mautino J, Vigo FS, Sommer B, Yankner BA. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci 2000; 3: 460-4.
27. Ueno M, Nakagawa T, Huang C, Ueki M, Kusaka T, Hosomi N, Kanenishi K, Onodera M, Wu B, Sakamoto H. The expression of P-glycoprotein is increased in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model. Neuropathol Appl Neurobiol 2009; 35: 147-55.
28. Ueno M, Wu B, Nakagawa T, Nagai Y, Onodera M, Huang C, Kusaka T, Kanenishi K, Sakamoto H. The expression of LDL receptor in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model. Histochem Cell Biol 2010; 133: 669-76.
29. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785-91.
30. Bonen A, Campbell SE, Benton CR, Chabowski A, Coort SL, Han XX, Koonen DP, Glatz JF, Luiken JJ. Regulation of fatty acid transport by fatty acid translocase/CD36. Proc Nutr Soc 2004; 63: 245-9.
31. Campbell SE, Tandon NN, Woldegiorgis G, Luiken JJ, Glatz JF, Bonen A. A novel function for fatty acid translocase (FAT)/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem 2004; 279: 36235-41.
32. Roepstorff C, WulffHelge J, Vistisen B, Kiens B. Studies of plasma membrane fatty acid-binding protein and other lipid-binding proteins in human skeletal muscle. Proc Nutr Soc 2004; 63: 239-44.
33. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu YH, Cook RF, Sargiacomo M. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 1994; 126: 111-26.
34. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000; 275: 11278-83.
35. Hirano K, Kuwasako T, Nakagawa-Toyama Y, Janabi M, Yamashita S, Matsuzawa Y. Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc Med 2003; 13: 136-41.
36. Medeiros LA, Khan T, El Khoury JB, Pham CL, Hatters DM, Howlett GJ, Lopez R, O'Brien KD, Moore KJ. Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J Biol Chem 2004; 279: 10643-8.
37. Cho S, Park E-M, Febbraio M, Anrather J, Park L, Racchumi G, Silverstein RL, Iadecola C. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci 2005; 25: 2504-12.
38. Pires PW, Deutsch C, McClain JL, Rogers CT, Dorrance AM. Tempol, a superoxide dismutase mimetic, prevents cerebral vessels remodeling in hypertensive rats. Microvasc Res 2010; 80: 445-52.
39. Iwanaga Y, Ueno M, Ueki M, Huang C, Tomita S, Okamoto Y, Ogawa T, Ueda N, Maekawa N, Sakamoto H. The osteopontin is increased in vessels with blood-brain barrier impairment. Neuropathol Appl Neurobiol 2008; 34: 145-54.
40. Newman GR, Jasani B, Williams ED. A simple post-embedding system for the rapid demonstration of tissue antigens under the electron microscope. Histochem J 1983; 15: 543-55.
41. Bendayan M, Nanci A, Kan FW. Effect of tissue processing on colloidal gold cytochemistry. J Histochem Cytochem 1987; 35: 983-96.
42. Moore KJ, El-Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW. A CD36-initiated signaling cascade mediates inflammatory effects of β-amyloid. J Biol Chem 2002; 277: 47373-9.
43. El Khoury JB, Moore KJ, Means TK, Leung J, Terada M, Toft M, Freeman MW, Luster AD. CD36 mediates the innate host response to β-amyloid. J Exp Med 2003; 197: 1657-66.
44. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor, CD36, protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 1049-56.
45. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 2333-8.
46. Silverstein RL, Li W, Park YM, Rahaman SO. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans Am Clin Climatol Assoc 2010; 121: 206-20.
47. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant atress and a pro-thrombotic phenotype. Nat Med 2007; 13: 1086-95.
48. Silverstein RL. Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress. Clin Lipidol 2009; 4: 767.
49. Fuhrman B, Volkova N, Aviram M. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and paraoxonase. Atherosclerosis 2002; 161: 307-16.
50. Venugopal SK, Devaraj S, Jialal I. RRR-alpha-tocopherol decreases the expression of the major scavenger receptor, CD36, in human macrophages via inhibition of tyrosine kinase (Tyk2). Atherosclerosis 2004; 175: 213-20.
51. Ricciarelli R, Zingg JM, Azzi A. Vitamine E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultures aortic smooth muscle cells. Circulation 2000; 102: 82-7.
52. Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. A novel cell-permeable antioxidant peptides, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem 2007; 282: 4634-42.
53. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004; 279: 34682-90.